[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"brand-junshishengwu":3},{"head":4,"company":41,"invest":46,"children":47,"shops":48,"category":49,"sameIndustry":5,"rid":6},{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"brandId":6,"brandLogo":7,"brandImage":5,"brandName":8,"webName":9,"balias":5,"enterId":10,"mainindustry":11,"industry":5,"brandType":12,"brandHonor":5,"brandTel":13,"establishdate":14,"brandBirth":15,"cityarea":5,"brandWebsite":5,"brandSobp":5,"brandVisit":5,"totalVisits":16,"status":17,"isDeleted":17,"comment":5,"remark":5,"logoExistStatus":18,"imageExistStatus":18,"industryId":5,"industryRanking":5,"score":5,"enterName":19,"mallShopList":20,"brandSummary":21,"likes":5,"unlikes":5,"follow":5,"pagetitle":22,"pagekeywords":23,"pagedesc":24,"brandContent":25,"province":5,"city":5,"area":5,"detailaddress":26,"unifiedscc":27,"enterType":28,"enterLegalperson":29,"enterStablishdate":30,"regauthority":31,"licenseValidity":32,"approvaldate":33,"regcapital":34,"incapital":35,"businessscope":36,"ownBrand":5,"enterTelphone":37,"enterWebsite":38,"business":39,"enterQq":5,"enterMail":40,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"regtrademark":5},null,"90411","\u002Fprofile\u002Fupload\u002F2025\u002F01\u002F25\u002F4e0b7d674311156e0b0f6594894f91d5.gif","君实生物","junshishengwu",89020,10006,3,"400-008-0866","2012年","上海市",434,0,"1","上海君实生物医药科技股份有限公司",[],"知名创新驱动型生物制药公司,致力于创新药物的发现和开发以及全球范围内的临床研发及商业化,在肿瘤免疫疗法\u002F自身免疫性疾病及代谢疾病治疗方面处于先进地位,上海君实生物医药科技股份有限公司","君实生物简介-君实生物科技-品牌之家","君实生物品牌介绍,君实生物科技好不好,君实怎么样,君实,上海君实生物医药科技股份有限公司","君实生物品牌简介，品牌之家为你介绍上海君实生物医药科技股份有限公司旗下君实生物品牌信息，包括品牌介绍、联系方式、主营产品、最新评论、点赞数量等，告诉你君实生物科技怎么样，致力于帮助你了解君实生物真实有效的品牌相关信息。","知名创新驱动型生物制药公司，致力于创新药物的发现和开发以及全球范围内的临床研发及商业化，在肿瘤免疫疗法、自身免疫性疾病及代谢疾病治疗方面处于先进地位\n\n君实生物是一家创新驱动型生物制药公司，致力于创新药物的发现和开发，以及在全球范围内的临床研发及商业化。公司的宗旨是为患者提供效果更好、花费更低的治疗选择。利用蛋白质工程的核心平台技术，我们已处在大分子药物的研发前沿。在中国区域内，凭借卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术及迅速扩大具市场潜力的在研药品组合，我们在肿瘤免疫疗法、自身免疫性疾病及代谢疾病治疗方面处于前沿地位。我们是国内焦躁获得抗PD-1单克隆抗体NMPA上市批准、抗PCSK9单克隆抗体NMPA临床申请批准的中国公司，并取得了治疗肿瘤抗BTLA阻断抗体在中国NMPA和美国FDA的临床申请批准。我们旨在通过源头创新来开发首创(First-in-class)或同类较优(Best-in-class)的药物，并成为转化医学领域的先锋。随着产品管线的丰富及对药物联合治疗的探索，预计我们的创新领域将扩展至包括小分子药物和抗体药物偶联物（或ADCs）等更多类型的药物研发，以及对癌症和自身免疫性疾病下一代创新疗法的探索。\n\n君实生物在上海和苏州，美国旧金山和马里兰建成四个研发中心；在苏州吴江和上海临港设立两个生产基地，基地采用国际先进的一次性生产技术。其中吴江生产基地拥有3,000升发酵能力并获得GMP认证，正在进行公司产品的商业化生产和临床试验用药的生产；临港生产基地按照cGMP标准建设，一期项目拥有30,000升发酵能力，于2019年底获得《药品生产许可证》。","中国（上海）自由贸易试验区蔡伦路987号4层","91310000059383413A","股份有限公司(港澳台投资、上市)","熊俊","2012-12-27","上海市市场监督管理局","-","2025-03-17","98,568.9871万(元)","1,470万(元)","生物医药的研发，并提供相关的技术开发、技术咨询、技术转让、技术服务，从事货物及技术的进出口业务。药品批发，药品委托生产。（详见药品上市许可持有人药品注册批件）【依法须经批准的项目，经相关部门批准后方可开展经营活动】","021-61058800","www.junshipharma.com","科技推广和应用服务业","jinzhou_liu@junshipharma.com",{"enterId":42,"enterName":19,"province":5,"city":5,"area":5,"detailaddress":26,"unifiedscc":27,"enterType":28,"enterLegalperson":29,"enterStablishdate":30,"regauthority":31,"licenseValidity":32,"approvaldate":33,"regcapital":34,"incapital":35,"businessscope":36,"ownBrand":5,"enterTelphone":37,"enterWebsite":38,"business":39,"performance":43,"socialSecurity":44,"registrationNumber":45,"enterQq":5,"enterMail":40,"bindUser":5,"enterMployeenum":5,"regcapitalunit":5,"abnormal":5,"yeartax":5,"status":17,"regtrademark":5,"remark":5},"89020","开业","384人","310115002060080",{"createTime":5,"updateTime":5,"createBy":5,"updateBy":5,"id":5,"brandId":5,"brandName":5,"busmodel":5,"franchiseFund":5,"totalStores":5,"devmodel":5,"franchiseIndustry":5,"investmenttel":5,"suitablePeople":5,"state":5},[],[],[50,68],{"createTime":51,"updateTime":52,"createBy":5,"updateBy":5,"industryId":53,"webId":5,"industryName":54,"industryAlias":55,"industryIcon":5,"industryTrans":56,"pageTitle":57,"pageDesc":58,"pageKeywords":59,"mainTitle":60,"pageSubtitle":61,"indSummary":62,"industryLevel":12,"parentId":63,"parentName":64,"sortOrder":65,"status":17,"classifyVisit":66,"totalVisits":67,"searchName":5,"starLevel":5,"limit":5},"2000-01-01 00:00:00","2026-06-14 16:50:00","5593","药品","药品,药物,医药制剂,医疗药品,医用药品,药片","\u002Fprofile\u002Fupload\u002F2023\u002F11\u002F08\u002F175454c1767ce2414a13f8c3c16194de.png","十大药品品牌-药品十大厂家-ZGALL品牌榜","2026年药品行业十大品牌权威发布！药品排行榜前十名品牌有三九、同仁堂、广药白云山、云南白药、太极药业、修正、念慈菴、天士力、扬子江药业、仁和。药品10大品牌由品牌中国重磅推出，旨在呈现行业领域标杆品牌，展现行业优秀企业实力，帮助你了解药品哪个牌子好。","药品十大品牌排名,OTC药品十大品牌,非处方药品牌十大排行榜,OTC药品排行,药品品牌有哪些","药品品牌排行榜","2026药品品牌排行榜，OTC药品排行，OTC常用药品有哪些","药品什么牌子好？品牌TOP榜权威发布2026年药品十大品牌名录；居前十的有：三九999、同仁堂、广药白云山、云南白药、太极药业TAIJI、修正、京都念慈菴、天士力TASLY、扬子江药业、仁和药业RenHe等，【行业品牌名录】基于大数据与人工智能技术，整合300+国际权威榜单及企业申报数据，通过算法分析市场占有率、创新力等12项指标，并解析超百万条舆情信息，采用加权模型（算法60%+专家30%+用户10%）生成动态排名。数据月度更新，申报需通过ISO认证审核，排名不分先后，仅供参考。",1411,"医药用品",20,4,1049,{"createTime":51,"updateTime":69,"createBy":5,"updateBy":5,"industryId":70,"webId":5,"industryName":71,"industryAlias":5,"industryIcon":5,"industryTrans":72,"pageTitle":73,"pageDesc":74,"pageKeywords":75,"mainTitle":76,"pageSubtitle":77,"indSummary":78,"industryLevel":12,"parentId":63,"parentName":5,"sortOrder":79,"status":17,"classifyVisit":5,"totalVisits":80,"searchName":5,"starLevel":5,"limit":5},"2026-06-16 16:50:00","10006","生物科技","\u002Fprofile\u002Fupload\u002F2023\u002F11\u002F08\u002F19f46e89d8cd077b73c7adb33bb2b59f.png","生物科技公司十大排行榜-国内知名生物科技公司有哪些-ZGALL品牌榜","2026年十大生物科技公司排行榜最新发布，生物科技公司十大排行榜前十名有中国生物、中国生物制药、百济神州、恒瑞、豪森药业、百利天恒、康方、复星医药、石药、信达。生物科技十大品牌排行榜由品牌研究部门收集整理大数据分析研究得出，帮助你了解中国生物科技公司有哪些。","生物科技公司排名前十有哪些,中国生物科技公司排名前十,生物科技有限公司排名,中国生物科技公司排名,全国生物科技公司排名","生物科技品牌排行榜","2026生物科技公司，生物制药公司排行榜，国内生物医药科技公司有哪些","生物科技哪个好？品牌TOP榜权威发布2026年生物科技名录；居前十的有：中国生物CNBG、中国生物制药、百济神州BeiGene、恒瑞医药、豪森药业、百利天恒、康方Akesobio、复星医药、石药CSPC、信达生物Innovent等，【行业品牌名录】基于大数据与人工智能技术，整合300+国际权威榜单及企业申报数据，通过算法分析市场占有率、创新力等12项指标，并解析超百万条舆情信息，采用加权模型（算法60%+专家30%+用户10%）生成动态排名。数据月度更新，申报需通过ISO认证审核，排名不分先后，仅供参考。",99,589]